Our expert comment this month looks at personalised medicine, but more from a business point of view than a medical one. As LSIPR readers will know, personalised medicine is all about tailoring treatment to the individual, and that, of course, can be extremely complicated.
Law firm Simmons & Simmons has expanded its Düsseldorf office with the addition of a new partner.
English High Court Justice Philip James Sales has found a patent covering AstraZeneca’s bestselling drug Symbicort invalid after a challenge by Israeli generic drug maker Teva.
WilmerHale has added life sciences lawyer and IP litigation specialist Anthony Trenton to its practice in London.
Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29).
The FDA has accepted applications by generic drug makers Mylan and Novartis subsidiary Sandoz for a three-times-weekly version of blockbuster drug Copaxone, it was announced yesterday.
Novartis Pharmaceuticals has launched a lawsuit against generics company Zydus Noveltech and its subsidiaries, accusing them of infringing patents relating to a drug used to treat Alzheimer’s and Parkinson’s disease.
The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid.
The US District Court for the District of New Jersey has ruled that Actavis may not launch a generic version of California-based Depomed’s Gralise (gabapentin), it has been announced.
The molecular diagnostic testing company GeneDx has petitioned the US Patent and Trademark Office to invalidate 11 patents asserted by Myriad in a lawsuit filed against GeneDx in October 2013.